Related Experiment Video

Updated: Mar 26, 2026

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
09:29

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice

Published on: July 14, 2023

1.3K

Using the galectin-3 test to predict mortality in heart failure patients: a systematic review and meta-analysis

Yueh-Sheng Chen1, Weng-Tein Gi2, Tin-Yun Liao3

  • 1Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.

Biomarkers in Medicine
|February 11, 2016
PubMed

Insights

Galectin-3 (Gal-3) shows potential for predicting mortality in heart failure (HF) patients. However, this biomarker should not be used alone for prognosis evaluation in HF.

Area of Science:

  • Cardiology
  • Biomarker Research
  • Medical Prognostics

Background:

  • Galectin-3 (Gal-3) is emerging as a significant biomarker for heart failure (HF) prognosis.
  • Accurate prognostic assessment is crucial for managing HF patients effectively.

Purpose of the Study:

  • To systematically review and meta-analyze the ability of Galectin-3 to predict prognosis in heart failure patients.
  • To evaluate Gal-3's performance in both acute and chronic heart failure settings.

Main Methods:

  • Comprehensive literature search of MEDLINE and Embase databases up to November 2014.
  • Analysis of test performance characteristics using forest plots.
  • Application of hierarchical summary receiver operating characteristic (HSROC) curves.

Main Results:

  • Galectin-3 demonstrated a diagnostic odds ratio of 2.36 (95% CI: 1.71-3.26) for predicting mortality in chronic HF.
  • The diagnostic odds ratio for predicting mortality in acute HF patients was 2.30 (95% CI: 1.76-3.01).

Conclusions:

  • Elevated Galectin-3 levels are significantly associated with increased mortality risk in both acute and chronic HF.
  • Current evidence suggests Gal-3 is a valuable prognostic marker but should not be the sole basis for HF prognosis evaluation.
Abstract

Keywords:
Galectin-3heart failureprognostic marker

More Related Videos

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

765
Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure04:20

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure

Published on: October 1, 2019

6.4K

Related Concept Videos

Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
830
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
414
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
574
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.2K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
671